Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Non-Small-Cell Lung Cancer – Current Treatment – Current Treatment: Physician Insights – Non-Small-Cell Lung Cancer (EU5) – 2020
The current treatment algorithm for non-small-cell lung cancer (NSCLC) is rapidly evolving. The increasing number of biomarker-driven therapies has resulted in a highly segmented space dominated by…
Non-Small-Cell Lung Cancer – Access & Reimbursement – Access & Reimbursement – Non-Small-Cell Lung Cancer (US)
The high number of premium-priced non-small-cell lung cancer (NSCLC) therapies and the large number of NSCLC patients have resulted in a significant financial burden for payers. Costs are set to…
Colorectal Cancer – Access & Reimbursement – Access & Reimbursement – Colorectal Cancer (US)
Seven premium-priced therapies (Avastin, Erbitux, Vectibix, Zaltrap, Stivarga, Lonsurf, and Cyramza) and three immune checkpoint inhibitors (Keytruda, Opdivo, and Yervoy) are FDA-approved to treat…
Squamous Cell Carcinoma of the Head and Neck – Current Treatment – Current Treatment: Physician Insights – Squamous Cell Carcinoma of the Head and Neck (US)
Immune checkpoint inhibitors have transformed the treatment algorithm for recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (SCCHN) and diversified treatment…
Squamous Cell Carcinoma of the Head and Neck – Current Treatment – Treatment Sequencing – Squamous Cell Carcinoma of the Head and Neck (US)
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand which drugs to position…
Non-Small-Cell Lung Cancer – Access & Reimbursement – Access & Reimbursement – Non-Small-Cell Lung Cancer (EU)
MARKET OUTLOOKNon-small-cell lung cancer (NSCLC) has a high incidence and a large number of premium-priced therapies, which results in a significant financial burden on payers. Costs are set to…
Breast Cancer – Access & Reimbursement – Access & Reimbursement – Optimizing Market Access Amid an Evolving Landscape for HR+/HER2- Therapies (EU)
MARKET OUTLOOKThe lucrative HR-positive, HER2-negative breast cancer market in Europe is fast-moving and competitive. CDK4/6 inhibitors Ibrance (Pfizer), Kisqali (Novartis) and Verzenios (Eli Lilly…
